Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Andreas Syggros Hospital of Venereal and Dermatological Diseases | OTHER |
Not provided
Not provided
Not provided
Data on the antiatherogenic effect of IL23 inhibitors are sparse. This study aimed to assess the impact of one-year treatment with an IL17 or IL23 inhibitor on arterial stiffness in patients with moderate-to-severe psoriasis.
This observational cohort study included patients with moderate-to-severe psoriasis treated with either an IL17 inhibitor or an IL23 inhibitor or a conventional systemic agent/apremilast (control group) for 52 weeks. The primary outcome was the evaluation of changes in carotid-femoral pulse wave velocity (PWV) and augmentation index normalized to 75 beats/min (AIx75) after 24 and 52 weeks. Secondary outcomes were the comparison of change in PWV and AIx75 between the study groups and the assessment of psoriasis disease severity scores and in ankle-brachial index (ABI).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 | IL17 inhibitor |
| |
| Group 2 | IL23 inhibitor |
| |
| Group 3 | conventional systemic agent or apremilast |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| interleukin 17 inhibitor | Drug | 52 weeks |
| |
| interleukin-23 inhibitor |
| Measure | Description | Time Frame |
|---|---|---|
| change of pulse wave velocity (PWV) from baseline to week 24 and 52 | PWV can range from approximately 6.6 m/s in patients under 30 to 11.7 m/s in patients over 70 years of age; higher scores mean a worse outcome | from enrollment to the end of treatment at week 52 |
| change of augmentation index normalized to 75 beats/min (AIx75) from baseline to week 24 and 52 | no single universally accepted normal range for an AIx@75; lower values indicate better arterial health, with values below 20-25% often considered optimal, and values above 30% associated with increased arterial stiffness and cardiovascular risk | from enrollment to the end of treatment at week 52 |
| Measure | Description | Time Frame |
|---|---|---|
| comparison of change in PWV between the study groups | From enrollment to the end of treatment at 52 weeks | |
| change in psoriasis area severity index (PASI) | range 0-72; higher scores mean a worse outcome |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Consecutive patients with plaque psoriasis with or without psoriatic arthritis, who were monitored in the outpatient department for psoriasis of "Andreas Syngros" hospital for skin diseases and were planed to start treatment with an IL17 inhibitor or an IL23 inhibitor on a conventional systemic agent/apremilast
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Andreas Sygros Hospital | Athens | 17124 | Greece |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41060491 | Derived | Tsiogka A, Soulaidopoulos S, Gregoriou S, Rompoti N, Panagakis P, Papoutsaki M, Kostakis P, Kontochristopoulos G, Tsioufis K, Vlachopoulos C, Stratigos A, Rigopoulos D. Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study. Dermatol Ther (Heidelb). 2025 Dec;15(12):3777-3792. doi: 10.1007/s13555-025-01549-1. Epub 2025 Oct 8. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP_ICF | Yes | Yes | Yes | Study Protocol, Statistical Analysis Plan, and Informed Consent Form | Jul 1, 2021 |
Not provided
Not provided
Not provided
Not provided
| Drug |
52 weeks |
|
| conventional systemic agent or apremilast | Drug | 52 weeks |
|
| From enrollment to the end of treatment at 52 weeks |
| change in ankle-brachial index (ABI) | range 0.9-1.4; higher scores mean worse outcome | From enrollment to the end of treatment at 52 weeks |
| comparison of change in AIx75 between the study groups | from enrollment to the end of treatment at 52 weeks |
| change in body surface area (BSA) | values 0-100%, higher scores mean a worse outcome | From enrollment to the end of treatment at 52 weeks |
| change in physician's global assessment (PGA) | range 0-5; higher scores mean a worse outcome | From enrollment to the end of treatment at 52 weeks |
| change in dermatology life quality index (DLQI) | range 0-30; higher scores mean a worse outcome | From enrollment to the end of treatment at 52 weeks |
| Aug 27, 2025 |
| Prot_SAP_ICF_000.pdf |
| ID | Term |
|---|---|
| D011565 | Psoriasis |
| D002318 | Cardiovascular Diseases |
| D050197 | Atherosclerosis |
| D015535 | Arthritis, Psoriatic |
| ID | Term |
|---|---|
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D025242 | Spondylarthropathies |
| D025241 | Spondylarthritis |
| D013166 | Spondylitis |
| D013122 | Spinal Diseases |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C505730 | apremilast |
Not provided
Not provided
Not provided